Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | FSHR | P23945 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224447 | 0.91 | HCRTR1 (0.36) | CYP1A2CYP2C9CYP2C19TSHRFSHR | |
| SCHEMBL6496346 | 0.69 | KMT2A (0.39) | TSHRBRD4ALDH1A1HSD17B3MEN1 | |
| SCHEMBL9160614 | 0.68 | KMT2A (0.39) | TSHRBRD4GAAALDH1A1LMNA | |
| SCHEMBL9162432 | 0.67 | KMT2A (0.40) | TSHRBRD4ALDH1A1LMNAHSD17B3 | |
| SCHEMBL31693867 | 0.65 | RORC (0.47) | CYP1A2CYP2C19TSHR | |
| SCHEMBL6496004 | 0.64 | ALDH1A1 (0.49) | TSHRBRD4GAAALDH1A1MEN1 | |
| SCHEMBL22461274 | 0.62 | KRAS (0.37) | CYP1A2CYP2C9CYP2C19TSHRGAA | |
| SCHEMBL4116338 | 0.62 | SMN1; SMN2 (0.47) | TSHRLMNAMEN1KMT2A | |
| SCHEMBL11272554 | 0.60 | TP53 (0.45) | GAAALDH1A1LMNATP53MEN1 | |
| SCHEMBL13312374 | 0.59 | BRD4 (0.44) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791090-B2 | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient | KOWA COMPANY, LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | CYP1A2 2178/4885CYP2C9 3116/4885CYP2C19 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.